New U of M start-up may save lives of victims of massive blood loss and trauma

A new technology from the University of Minnesota has resulted in a startup that may help prolong the lives of victims suffering from massive blood loss or trauma. The university's Office for Technology Commercialization has signed a license agreement with Denver-based Ariel Pharmaceuticals authorizing the private company to develop and commercialize the therapy.

Researchers at the Twin Cities and Duluth campuses — including surgeon Gregory Beilman, biologist Matthew Andrews and biomedical scientist Lester Drewes — designed a low-volume resuscitation fluid that may increase the survival rates of people who die from hemorrhagic shock. They developed the therapy, called Tamiasyn, based on their studies of the biological process of hibernation in ground squirrels (gophers).

"We're excited to have the opportunity to further develop the technology and we're confident this unique therapeutic approach will provide patients with a better chance of survival," said Steve Orndorff, president and CEO of Ariel Pharmaceuticals.

The technology could offer first responders, emergency department staff and military medics a simple, safe and reliable product that prevents life-threatening complications due to severe . At the same time, it could help prevent organ damage during resuscitation.

"Licensing with a private pharmaceutical company is the next step in bringing this drug to the marketplace and, more importantly, in bringing this drug first into the hands of the military personnel in harm's way," said Andrews. "Ariel Pharmaceuticals' expertise will shepherd our proposed therapy through the clinical approval to the point that our research begins to save lives."

add to favorites email to friend print save as pdf

Related Stories

Nanoparticles increase survival after blood loss

Feb 22, 2011

In an advance that could improve battlefield and trauma care, scientists at Albert Einstein College of Medicine of Yeshiva University have used tiny particles called nanoparticles to improve survival after life-threatening ...

Recommended for you

Were clinical trial practices in East Germany questionable?

Oct 23, 2014

Clinical trials carried out in the former East Germany in the second half of the 20th century were not always with the full knowledge or understanding of participants with some questionable practices taking place, according ...

Schumacher's doctor sees progress after injury

Oct 23, 2014

A French physician who treated Michael Schumacher for nearly six months after the Formula One champion struck his head in a ski accident says he is no longer in a coma and predicted a possible recovery within three years.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Who_Wants_to_Know
not rated yet Oct 19, 2011
Note to author - ref: your sentence "may increase the survival rates of people who die from hemorrhagic shock." You can't save the life of those who die. You can only increase the survival rate of those AT RISK of death, or of those who WOULD OTHERWISE BE LIKELY to die. You can't do anything about those who die - they're dead. Semantics. Logic. Meaning of words.